GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma (NeoPancOne)

Status:

Opening Soon

Phase

Neoadjuvant

Line of Therapy

Early Cancer

Disease Stage

Biomarker(s)

N/A

Investigational

Product

Modified Folforinox (mFFX)

Treatment Arms

Single Group Assignment:

Neo-adjuvant mFFX for up to 6 cycles, chemo-Adjuvant FFX q 2 weekly or other approach as per investigator to complete up to 6 months chemotherapy